MannKind Corporation to Present Positive Research Data on Inhaled Insulin Afrezza at ATTD Conference

Summary

MannKind Corporation will present data on the inhalable insulin Afrezza at the ATTD conference from March 19-22, 2025. Five presentations will feature positive results from studies involving children (inhale-1) and adults (inhale-3), demonstrating Afrezza’s efficacy and safety. A supplemental new drug application (sNDA) for pediatric use is expected to be submitted in 2025. The conference will discuss the benefits of inhalable insulin, with MannKind’s clinical education team engaging in scientific exchange at Booth 40.

Impact Analysis

The presentation at the ATTD conference is a product milestone for MannKind Corporation, focusing on the inhalable insulin Afrezza. First-order effects include increased visibility and credibility in the diabetes treatment market due to positive study results, potentially leading to a successful sNDA submission for pediatric use, expanding Afrezza’s market. The second-order effects involve enhanced competitive positioning against traditional insulin treatments, which often involve syringes or insulin pumps, presenting a more convenient solution for patients. Investment opportunities could arise from the potential market expansion and the adoption of Afrezza as a preferred treatment option in the diabetes care sector.